Related Experiment Video
Updated: May 5, 2026

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
Published on: May 11, 2014
Diagnostic and Prognostic Biomarkers for Barrett's Esophagus
Fangfang Wang1, Allon Kahn1, John B Kisiel2
1Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, USA.
None:
The increasing burden of esophageal adenocarcinoma (EAC) has driven efforts to improve early detection and risk stratification. Barrett's esophagus (BE), the only known precursor to EAC, presents an opportunity for screening and surveillance. This article highlights major advances in molecular biomarkers for BE, such as the Cytosponge-TFF3 test, methylated DNA markers, p53, aneuploidy, and other emerging biomarkers. Their integration into clinical practice may transform esophageal cancer detection and prevention by enabling precision screening and surveillance and by broadening access to care.
Related Concept Videos
Barrett Esophagus-I: Introduction
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

